
Vaibhav A Narayan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/522765/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. Pattern Recognition, 2022, 123, 108403.	8.1	26
2	Daily steps and depressive symptoms: A longitudinal evaluation of patients with major depressive disorder in the precision medicine in mental health care study. Journal of Affective Disorders, 2022, 300, 334-340.	4.1	4
3	The Association Between Home Stay and Symptom Severity in Major Depressive Disorder: Preliminary Findings From a Multicenter Observational Study Using Geolocation Data From Smartphones. JMIR MHealth and UHealth, 2022, 10, e28095.	3.7	19
4	Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): recruitment, retention, and data availability in a longitudinal remote measurement study. BMC Psychiatry, 2022, 22, 136.	2.6	42
5	Longitudinal Relationships Between Depressive Symptom Severity and Phone-Measured Mobility: Dynamic Structural Equation Modeling Study. JMIR Mental Health, 2022, 9, e34898.	3.3	26
6	P382. Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Digital Biomarkers. Biological Psychiatry, 2022, 91, S241-S242.	1.3	1
7	Relationship Between Major Depression Symptom Severity and Sleep Collected Using a Wristband Wearable Device: Multicenter Longitudinal Observational Study. JMIR MHealth and UHealth, 2021, 9, e24604.	3.7	35
8	Predicting Depressive Symptom Severity Through Individuals' Nearby Bluetooth Device Count Data Collected by Mobile Phones: Preliminary Longitudinal Study. JMIR MHealth and UHealth, 2021, 9, e29840.	3.7	26
9	Clinical Utility of Wearable Sensors and Patient-Reported Surveys in Patients With Schizophrenia: Noninterventional, Observational Study. JMIR Mental Health, 2021, 8, e26234.	3.3	6
10	A randomized, multicenter, crossover psychometric evaluation study of an iPad-administered cognitive test battery in participants with major depressive disorder who responded to treatment with oral antidepressants. Journal of Affective Disorders, 2021, 292, 261-269.	4.1	0
11	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurological Sciences, 2020, 41, 1647-1650.	1.9	48
12	Patients' Measurement Priorities for Remote Measurement Technologies to Aid Chronic Health Conditions: Qualitative Analysis. JMIR MHealth and UHealth, 2020, 8, e15086.	3.7	7
13	Human-Centered Design Strategies for Device Selection in mHealth Programs: Development of a Novel Framework and Case Study. JMIR MHealth and UHealth, 2020, 8, e16043.	3.7	31
14	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. Journal of Medical Internet Research, 2020, 22, e19992.	4.3	155
15	Phenotypic analysis of 23andMe survey data: Treatment-resistant depression from participants' perspective. Psychiatry Research, 2019, 278, 173-179.	3.3	6
16	Longitudinal Modeling of Functional Decline Associated with Pathologic Alzheimer's Disease in Older Persons without Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 62, 855-865.	2.6	5
17	Mobile and pervasive computing technologies and the future of Alzheimer's clinical trials. Npj Digital Medicine, 2018, 1, 1.	10.9	197
18	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28

Vaibhav A Narayan

#	Article	IF	CITATIONS
19	Trajectories and changes in individual items of positive and negative syndrome scale among schizophrenia patients prior to impending relapse. NPJ Schizophrenia, 2018, 4, 10.	3.6	24
20	Predictive modeling of treatment resistant depression using data from STAR*D and an independent clinical study. PLoS ONE, 2018, 13, e0197268.	2.5	42
21	554. Application of Growth Mixture Modeling in Antidepressant Treatment Response Studies. Biological Psychiatry, 2017, 81, S224.	1.3	0
22	lt's a long shot, but it just might work! Perspectives on the future of medicine. BMC Medicine, 2016, 14, 176.	5.5	17
23	Moving from 'diagnose and treat' to 'predict and pre-empt' in neuropsychiatric disorders. Nature Reviews Drug Discovery, 2016, 15, 71-72.	46.4	4
24	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. Journal of Alzheimer's Disease, 2015, 46, 1079-1089.	2.6	28
25	Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid AÎ21-42 Level. PLoS ONE, 2015, 10, e0134000.	2.5	39
26	Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer's subjects from the Alzheimer's Disease Neuroimaging Initiative. Neuropsychiatric Disease and Treatment, 2014, 10, 929.	2.2	45
27	Optimizing Regions-of-Interest Composites for Capturing Treatment Effects on Brain Amyloid in Clinical Trials. Journal of Alzheimer's Disease, 2014, 43, 809-821.	2.6	17
28	Harnessing the informatics revolution for neuroscience drug R&D. Nature Reviews Drug Discovery, 2014, 13, 561-562.	46.4	7
29	Modeling disease progression via multi-task learning. NeuroImage, 2013, 78, 233-248.	4.2	174
30	Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes. British Journal of Clinical Pharmacology, 2013, 75, 146-161.	2.4	43
31	Beyond magic bullets: true innovation in health care. Nature Reviews Drug Discovery, 2013, 12, 85-86.	46.4	15
32	Multi-source feature learning for joint analysis of incomplete multiple heterogeneous neuroimaging data. NeuroImage, 2012, 61, 622-632.	4.2	155
33	An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative. Journal of Clinical Pharmacology, 2012, 52, 629-644.	2.0	83
34	A Novel Subject Synchronization Clinical Trial Design for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 31, 507-516.	2.6	2
35	Quantifying the Pathophysiological Timeline of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 26, 745-753.	2.6	70
36	Integrating scientific data for drug discovery and development using the Life Sciences Grid. Expert Opinion on Drug Discovery, 2009, 4, 687-699.	5.0	2

#	Article	IF	CITATIONS
37	The Sequence of the Human Genome. Science, 2001, 291, 1304-1351.	12.6	12,623
38	A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae. Nature, 2000, 403, 623-627.	27.8	4,490
39	Structures of Zinc Finger Domains from Transcription Factor Sp1. Journal of Biological Chemistry, 1997, 272, 7801-7809.	3.4	115